Celularity Inc
For the period ended Sep 30, 2023. Filed Jan 3, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2023 · Filed Jan 3, 2024
CELU$0.71-6.4%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows
(Unaudited) (in thousands)
| Nine Months Ended September 30, | ||||
|---|---|---|---|---|
| 2023 · 2022 | ||||
| Cash flow from operating activities: | ||||
| Net loss | $(205,842) | $(10,242) | ||
| Adjustments to reconcile net loss to net cash used in operations: | ||||
| Depreciation and amortization | 7,028 | 6,997 | ||
| Non cash lease expense | (62) | (41) | ||
| Provision for doubtful accounts | 456 | 981 | ||
| Goodwill impairment | 112,347 | - | ||
| IPR&D impairment | 107,800 | - | ||
| Change in fair value of warrant liabilities | (6,788) | (31,613) | ||
| Stock-based compensation expense | 11,442 | 11,470 | ||
| Change in fair value of contingent consideration | (104,339) | (73,441) | ||
| Acquired in-process research and development | 3,000 | - | ||
| Issuance of common stock for stem-cells to be used in research and development | 1,000 | - | ||
| Issuance of common stock relating to Yorkville debt extension | 712 | - | ||
| Discounts arising from RWI loan arrangement - related party | 2,151 | - | ||
| Fair value of warrant modification for professional services | 403 | - | ||
| Change in fair value of contingent stock consideration | (159) | 415 | ||
| Change in fair value of debt | 354 | 291 | ||
| Other, net | 2,012 | (1,432) | ||
| Changes in assets and liabilities: | ||||
| Accounts receivable | (118) | (2,688) | ||
| Inventory | (1,605) | (16,830) | ||
| Prepaid expenses and other assets | 2,179 | 510 | ||
| Accounts payable | 6,754 | 297 | ||
| Accrued expenses and other liabilities | 1,533 | 6,546 | ||
| Accrued R&D Software | 24,161 | - | ||
| Right-of-use assets and lease liabilities | 172 | 195 | ||
| Deferred revenue | 1,065 | 294 | ||
| Net cash used in operating activities | (34,344) | (108,291) | ||
| Cash flow from investing activities: | ||||
| Capital expenditures | (468) | (4,457) | ||
| Purchase of acquired in-process research and development | (3,000) | - | ||
| Net cash used in investing activities | (3,468) | (4,457) | ||
| Cash flow from financing activities: | ||||
| Proceeds from RWI senior secured bridge loan and warrants - related party | 12,375 | - | ||
| Principal payments of Yorkville short-term debt | (16,811) | - | ||
| Proceeds from issuance of senior secured C.V. Starr bridge loan and warrants - related party | 4,994 | - | ||
| Proceeds from the exercise of stock options | 304 | 647 | ||
| Proceeds from the exercise of warrants | - | 46,490 | ||
| Proceeds from PIPE financings | 12,750 | 30,000 | ||
| Proceeds from the sale of common stock in ATM offering | 136 | 4,570 | ||
| Proceeds from other short-term debt | 2,000 | 39,200 | ||
| Proceeds from other short-term debt - related party | 1,000 | - | ||
| Tax withholding on vesting of restricted stock units | (87) | - | ||
| Proceeds from registered direct offerings | 9,000 | - | ||
| Payments of PIPE and other issuance costs | (1,553) | (2,754) | ||
| Net cash provided by financing activities | 24,108 | 118,153 | ||
| Net (decrease) increase in cash, cash equivalents and restricted cash | (13,704) | 5,405 | ||
| Cash, cash equivalents and restricted cash at beginning of period | 28,802 | 52,076 | ||
| Cash, cash equivalents and restricted cash at end of period | $15,098 | $57,481 | ||
| Supplemental disclosure of cash flow information: | ||||
| Cash paid for interest | $1,073 | $ | - | |
| Supplemental non-cash investing and financing activities: | ||||
| Property and equipment included in accounts payable and accrued expenses | $(752) | $(1,014) | ||
| Issuance of warrants on senior secured bridge loans | $2,002 | $ | - | |
| Common stock issued for short-term debt conversion | $4,599 | $ | - | |
| Reduction of right-of-use assets and associated lease liability due to lease modification | $(2,083) | $ | - | |
| ATM related costs included in accrued expenses | $ | - | $(234) | |
| PIPE related costs included in accrued expenses | $(69) | $(55) | ||
| Interest accrued on senior secured loans within long-term debt - related parties | $(1,229) | $ | - | |
| Reclassification of option liabilities to equity | $ | - | $441 | |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.